HomeComparePAVMW vs QYLD

PAVMW vs QYLD: Dividend Comparison 2026

PAVMW yields 6896.55% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PAVMW wins by $1432605808592863.25M in total portfolio value
10 years
PAVMW
PAVMW
● Live price
6896.55%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1432605808592863.25M
Annual income
$1,392,875,843,310,163,600,000.00
Full PAVMW calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — PAVMW vs QYLD

📍 PAVMW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPAVMWQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PAVMW + QYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PAVMW pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PAVMW
Annual income on $10K today (after 15% tax)
$586,206.90/yr
After 10yr DRIP, annual income (after tax)
$1,183,944,466,813,639,000,000.00/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, PAVMW beats the other by $1,183,944,466,813,639,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PAVMW + QYLD for your $10,000?

PAVMW: 50%QYLD: 50%
100% QYLD50/50100% PAVMW
Portfolio after 10yr
$716302904296431.63M
Annual income
$696,437,921,655,081,800,000.00/yr
Blended yield
97.23%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PAVMW right now

PAVMW
Analyst Ratings
4
Buy
Consensus: Buy
Altman Z
-11.3
Piotroski
3/9
QYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PAVMW buys
0
QYLD buys
0
No recent congressional trades found for PAVMW or QYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPAVMWQYLD
Forward yield6896.55%11.92%
Annual dividend / share$2.00$2.04
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$1432605808592863.25M$25.4K
Annual income after 10y$1,392,875,843,310,163,600,000.00$5,659.31
Total dividends collected$1429942114786334.00M$27.1K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: PAVMW vs QYLD ($10,000, DRIP)

YearPAVMW PortfolioPAVMW Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$700,355$689,655.17$10,352$1,192.36+$690.0KPAVMW
2$45,889,900$45,140,520.30$10,830$1,347.57+$45.88MPAVMW
3$2,813,379,172$2,764,276,978.38$11,460$1,539.07+$2813.37MPAVMW
4$161,393,449,836$158,383,134,122.24$12,275$1,777.84+$161393.44MPAVMW
5$8,664,159,276,546$8,491,468,285,221.65$13,323$2,078.95+$8664159.26MPAVMW
6$435,300,017,392,982$426,029,366,967,078.00$14,667$2,463.34+$435300017.38MPAVMW
7$20,469,824,923,231,620$20,004,053,904,621,130.00$16,396$2,960.57+$20469824923.22MPAVMW
8$901,046,035,934,427,400$879,143,323,266,569,700.00$18,631$3,612.97+$901046035934.41MPAVMW
9$37,130,808,675,420,410,000$36,166,689,416,970,576,000.00$21,548$4,482.15+$37130808675420.39MPAVMW
10$1,432,605,808,592,863,400,000$1,392,875,843,310,163,600,000.00$25,398$5,659.31+$1432605808592863.25MPAVMW

PAVMW vs QYLD: Complete Analysis 2026

PAVMWStock

PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE). Its product pipeline also comprises EsoGuard, a molecular diagnostic esophageal DNA test; EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; PortIO, an implantable intraosseous vascular access device; and DisappEAR, a resorbable pediatric ear tube, as well as NextCath and Caldus. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is based in New York, New York.

Full PAVMW Calculator →

QYLDETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this PAVMW vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PAVMW vs SCHDPAVMW vs JEPIPAVMW vs OPAVMW vs KOPAVMW vs MAINPAVMW vs XYLDPAVMW vs JEPQPAVMW vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.